Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rishi Kaushal

Interventional Cardiology Torrance, CA Medical Doctor

NPI 1477745578 CMS profile 860388

3475 Torrance Blvd, Suite A, Torrance, CA 90503

Open in the dashboard

General payments

$114,138

166 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Rishi Kaushal of Torrance, CA is reported in the CMS Open Payments database as having received $114,138 across 166 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $7,124 46
2024 General $5,952 29
2023 General $24,014 16
2022 General $71,208 50
2021 General $452 10
2020 General $67 4
2019 General $5,323 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rishi Kaushal
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Rishi Kaushal were reported at $7,124. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Rishi Kaushal Interventional Cardiology median Middle half National median
2019 $5,323 $1,097 $329–$3,048 $163
2020 $67 $473 $161–$1,480 $114
2021 $452 $677 $233–$1,827 $132
2022 $71,208 $978 $333–$2,724 $149
2023 $24,014 $1,136 $382–$2,986 $160
2024 $5,952 $1,181 $395–$3,326 $164
2025 $7,124 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Inari Medical, Inc. $100,290 58 payments
  2. Stryker Corporation $6,536 6 payments
  3. Abbott Laboratories $5,136 8 payments
  4. Boston Scientific Corporation $648 35 payments
  5. Medtronic, Inc. $398 27 payments
  6. Astellas Pharma US Inc $257 5 payments
  7. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $150 2 payments
  8. Shockwave Medical, Inc $145 4 payments
  9. Biotronik Inc. $124 2 payments
  10. Medtronic Vascular, Inc. $105 4 payments
  11. Other $349 15 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $71,025 22 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $28,762 8 payments
  3. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $5,000 2 payments
  4. Travel and Lodging $4,721 13 payments
  5. Food and Beverage $4,432 119 payments
  6. Education $198 2 payments
Products named General payments · program years 2019–2025
  1. FLOWTRIEVER CATHETER, S $106,624 61 payments
  2. CT THROMBECTOMY SYSTEM KIT $106,533 59 payments
  3. Xience V coronary stent system $5,000 2 payments
  4. Micra $338 24 payments
  5. AVVIGO Guidance System $211 13 payments
  6. CLOTTRIEVER BOLD CATHETER $173 1 payment
  7. LifeVest $150 2 payments
  8. ROTAPRO $118 6 payments
  9. Vascular Lithotripsy $117 3 payments
  10. Azure $105 4 payments
  11. Other $1,081 48 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 58 drugs

Part D claims

4,382

Median for Cardiology: 2,533

Drug cost

$863,067

Median for Cardiology: $485,213

Branded share of claims

25.8%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 300 $378,572
Jardiance Empagliflozin Brand 70 $100,161
Xarelto Rivaroxaban Brand 72 $98,505
Repatha Sureclick Evolocumab Brand 63 $60,346
Farxiga Dapagliflozin Propanediol Brand 45 $50,649
Entresto Sacubitril/Valsartan Brand 33 $42,935
Repatha Syringe Evolocumab Brand 35 $20,708
Brilinta Ticagrelor Brand 18 $20,455
Praluent Pen Alirocumab Brand 24 $15,023
Carvedilol Er Carvedilol Phosphate Brand 15 $5,763

The 10 drugs with the highest cost, of 58 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 89 billing codes

Paid by Medicare

$253,155

Medicare's payments for the services billed

Medicare patients

947

Average age 77

Services billed

3,332

452 women, 495 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 49%
Ischemic heart disease 48%
Diabetes 42%
Chronic kidney disease 35%
Heart failure 31%
Atrial fibrillation 31%
Depression 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

166 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record